Get the Stockscreener App
8.27
5.92%
-0.52
After Hours:
8.27
Cullinan Therapeutics Inc stock is traded at $8.27, with a volume of 461.29K.
It is down -5.92% in the last 24 hours and up +11.61% over the past month.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
See More
Previous Close:
$8.79
Open:
$8.76
24h Volume:
461.29K
Relative Volume:
1.04
Market Cap:
$457.66M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-2.2412
EPS:
-3.69
Net Cash Flow:
$-134.48M
1W Performance:
+6.64%
1M Performance:
+11.61%
6M Performance:
-48.25%
1Y Performance:
-70.83%
1-Day Range:
$8.26
$8.80
1-Week Range:
$7.70
$8.97
52-Week Range:
$6.85
$30.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
8.27 | 457.66M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Invesco Ltd. Buys 1,395 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Leerink Partnrs Brokers Increase Earnings Estimates for CGEM - Defense World
Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know - Yahoo Finance
Cullinan Therapeutics to begin US trial of CLN-978 to treat Sjögren’s disease - Yahoo Finance
Barclays PLC Has $2.99 Million Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Holdings Reduced by Legal & General Group Plc - Defense World
Cullinan Therapeutics to Initiate US Study of CLN-978 for Moderate to Severe Sjogren's Disease - marketscreener.com
Cullinan Therapeutics (CGEM) Begins Study of CLN-978 for Sjogren - GuruFocus
Cullinan Therapeutics to Initiate Study of CLN-978, a - GlobeNewswire
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Buy” from Brokerages - Defense World
SEC Form DEF 14A filed by Cullinan Therapeutics Inc. - Quantisnow
Shareholders Can't Ignore US$502k Of Sales By Cullinan Therapeutics Insiders - simplywall.st
JPMorgan Chase & Co. Buys 169,104 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (CGEM) to Present Promising Lung Cancer St - GuruFocus
Cullinan Therapeutics to Present Results from REZILIENT1, a Phas - GuruFocus
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 - The Manila Times
Cullinan Therapeutics to Present Positive REZILIENT1 Study Results of Zipalertinib for NSCLC at 2025 ASCO Annual Meeting - Nasdaq
Why Acquire Shares Of Cullinan Therapeutics Inc (CGEM)? - Marketing Sentinel
Geode Capital Management LLC Acquires 6,220 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Federated Hermes Inc. Boosts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
HC Wainwright Reiterates “Buy” Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics receives EMA approval for rheumatoid arthritis drug trial - Yahoo
EMA greenlights Cullinan’s arthritis drug trial in Europe By Investing.com - Investing.com South Africa
Cullinan gets EU nod to begin testing CLN-978 in rheumatoid arthritis - Seeking Alpha
Cullinan Therapeutics Receives Approval from European Medicines - GuruFocus
Cullinan Therapeutics (CGEM) Receives EMA Approval for Rheumatoid Arthritis Trial | CGEM Stock News - GuruFocus
EMA greenlights Cullinan’s arthritis drug trial in Europe - Investing.com
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis - GlobeNewswire
Vanguard Group Inc. Reduces Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Wellington Management Group LLP Has $1.62 Million Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
KLP Kapitalforvaltning AS Purchases Shares of 6,800 Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by American Century Companies Inc. - Defense World
Corebridge Financial Inc. Sells 1,941 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data - Seeking Alpha
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Buy” from Analysts - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Swiss National Bank - Defense World
Charles Schwab Investment Management Inc. Has $5.25 Million Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
20,273 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Purchased by Connor Clark & Lunn Investment Management Ltd. - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 2.1% – Time to Sell? - Defense World
EGFR Non-Small Cell Lung Cancer Clinical and Non-Clinical - openPR
Morgan Stanley Reaffirms Overweight Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Recommendation of “Buy” from Analysts - Defense World
Cullinan Therapeutics: Promising Pipeline and Upcoming Catalysts Justify Buy Rating - TipRanks
Rhumbline Advisers Raises Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
New York State Common Retirement Fund Buys 3,200 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):